Pooled HELIOS-A/HELIOS-B safety included 707 patients (30.3% hereditary; remainder wild-type) with median 33.4 months of therapy and exposure up to 58 months. Exposure-adjusted overall and serious ...
In early September 2025, Alnylam Pharmaceuticals announced and completed a US$575 million convertible zero coupon senior unsecured note offering due September 2028 and presented extensive long-term ...
Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results